EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Comparative functional and cognitive trajectories following second‐generation antipsychotic initiation among long‐term care residents with Alzheimer disease: A target trial emulation study

Chen Jiang, Josh Krivinko, Robert A. Sweet, Yu Deng, Ugochukwu Ezigbo, Ruihan Huang, Julia Kofler, Lirong Wang

Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2026-10 · 12 (4)

DOI: 10.1002/trc2.70347 ↗
AbstractBibliografische Angaben

Abstract

Abstract Introduction Real‐world evidence comparing the functional and cognitive outcomes associated with commonly prescribed second‐generation antipsychotics (SGAs) in long‐term care (LTC) residents with Alzheimer disease (AD) is limited. Methods We emulated target trials using linked LTC Data Cooperative and Medicare data. A total of 17,766 eligible new users initiating risperidone, quetiapine, olanzapine, or aripiprazole were compared under an intention‐to‐treat framework using inverse probability of treatment weighting and weighted generalized estimating equations. Outcomes were 12‐month trajectories of Activities of Daily Living (ADL) and Brief Interview for Mental Status (BIMS). Results ADL trajectories were similar across SGAs. In BIMS trajectory, quetiapine was associated with a modestly greater decline ( β = −0.203, 95% confidence interval [CI] −0.380 to −0.027) compared with aripiprazole. Age modified several comparative treatment effects, particularly for BIMS. Findings were consistent across sensitivity analyses. Discussion Long‐term functional and cognitive outcomes were broadly comparable across commonly prescribed SGAs. Age‐related heterogeneity in comparative treatment effects warrants further investigation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →